Core Viewpoint - 盛达资源 has demonstrated significant financial growth in 2024, with a revenue of 2.013 billion yuan and a net profit of 390 million yuan, marking a year-on-year increase of 163.56% and 85.74% respectively, reflecting the success of its multi-dimensional strategic layout [1] Financial Performance - In 2024, 盛达资源 achieved a revenue of 2.013 billion yuan, with a net profit of 390 million yuan, representing a year-on-year growth of 163.56% [1] - The company's non-recurring net profit reached 260 million yuan, up 85.74% year-on-year, indicating strong operational performance [1] - The revenue from non-ferrous metal selection business was 1.469 billion yuan, a year-on-year increase of 15.81%, accounting for 73% of total revenue [2] Industry Context - The silver market is experiencing a historic opportunity in 2024, with global silver demand for photovoltaic applications increasing by 20% to 7,217 tons, representing 19% of industrial demand [2] - Global silver supply has declined for three consecutive years, with a total production of 824 million ounces (approximately 25,637 tons) in 2024, down 0.8% year-on-year, leading to a supply-demand gap of 6,003 tons [2] - The price of silver has surpassed $28 per ounce, reaching a new high since 2012 due to the "demand explosion + tight supply" scenario [2] Resource Expansion and Development - 盛达资源 is actively expanding its resource base through continuous exploration and resource integration, enhancing its core competitiveness [3] - The company completed significant technical upgrades in its mining operations, which are expected to improve mining efficiency and safety [3] - By the end of 2024, the company’s silver reserves are nearly 10,000 tons, with an annual selection capacity of nearly 2 million tons, solidifying its position as a leader in the silver sector [4] Growth Drivers - 盛达资源 has taken a strategic step in the gold sector by acquiring a 53% stake in 鸿林矿业, which has significant copper and gold resources [5] - The 菜园子 copper-gold mine is expected to enter trial production between July and September 2025, which will enhance the company's growth potential [5] - The company anticipates a dual boost in performance and valuation with the gradual release of production capacity and the rise in precious metal prices [5]

中国化妆品行业的历史正式翻开新的篇章！ 4月2 4日晚间，珀莱雅发布的最新年报显示，其2 0 2 4年营收达到1 0 7 . 7 8亿元。刷新了中国本土 化妆品企业的最高营收纪录，也意味着中国本土化妆品企业正式进入百亿时代。 这一里程碑背后，是中国化妆品行业从"渠道为王"到"科研立命"的基因突变。经济学家郑永年 提出，未来1 0年，中国正面临"中等技术陷阱"的挑战——提升"从0到1 "的原创性创新能力， 以及在" 1 - 1 0 "技术刻度上持续升级，是企业博得可持续发展的关键。这一洞察同样适用于本土 美妆市场。 那 么 ， 在 跨 过 百 亿 规 模 之 后 的 未 来 十 年 ， 珀 莱 雅 又 有 哪 些 长 远 目 标 和 规 划 ？ 《 FBe a u t y 未 来 迹》专访珀莱雅首席科学官黄虎，试图从研发的视角探索这家本土美妆企业的战略性布局。 珀莱雅首席科学官 黄虎 据 《 FBe a u t y 未 来 迹 》 了 解 ， 在 跨 越 百 亿 门 槛 之 后 ， 珀 莱 雅 已 经 正 式 定 下 了 " 双 十 " 战 略 愿 景 ——" 未来十年跻身全球化妆品行业前十 "。 回 顾 历 ...

导读： 近日，大连理工大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出25项仪器设备采购意向， 预算总额达1.29亿元。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，大连理工大学发布25项仪器设备采购意向，预算总额达1.29亿元，涉及低温环境模拟与控制装置、电子万能材 料试验机、多功能组合疲劳试验装备、原位拉曼光谱设备、台式X射线吸收精细结构谱仪等，预计采购时间为2025年 4~12月。 大连理工大学2025年4~12月仪器设备采购意向汇总表 | 采购 | 需求概况 | 预算 | 采购 | | --- | --- | --- | --- | | 项目 | | 万元 | 时间 | | 空间滴状 | 采购"空间滴状冷凝传热实验模块"，包含"空间滴状冷凝 | | | | 冷凝传热 | 传热实验模块工程件"与"空间滴状冷凝传热实验模块飞行 | 343 | 2025年 | | 实验模块 | 件"，配套我国空间站的两相系统实验柜，实现滴状冷凝 | | 4月 | | | 传热实验研究 | | | | 复合材料 ...

Core Viewpoint - The company has signed a supply agreement for a new product, the cartridge bottle rubber sealing component, which is expected to positively impact its operating performance if executed successfully [1][4]. Group 1: Agreement Details - The company has entered into a supply agreement with a domestic pharmaceutical company, with an estimated order value of approximately 20 million RMB [2][3]. - The agreement is classified as a routine operational contract and does not require approval from the board of directors or shareholders [2]. - The agreement is set to be executed from the date of signing until December 31, 2025 [5]. Group 2: Product and Market Impact - The new product represents a breakthrough in key technologies through independent research and innovation, achieving commercial batch supply for the first time [1][4]. - The product's development demonstrates the company's research and development capabilities and aligns with international standards, enhancing its competitiveness in the pharmaceutical packaging market [1][4]. Group 3: Risk Analysis - The agreement includes clear stipulations regarding the amount, payment schedule, rights and obligations of both parties, and breach of contract responsibilities [6]. - Despite both parties having the capacity to fulfill the agreement, external factors such as macroeconomic changes, policy shifts, and unforeseen circumstances may affect execution [6].